Dr. Muhammad Sharjeel Usmani

Author of four books and over 100 peer-reviewed papers, Dr. Usmani is a pioneering figure in the field of nuclear medicine and radionuclide therapy. A graduate of the Nuclear Medicine Board of Kuwait and holding an MSc from Islamabad, Pakistan, he has been instrumental in the development of theranostics, SPECT/CT, and PET/CT technology in Kuwait since the late 2000s. As a consultant nuclear medicine physician at the Sultan Qaboos Comprehensive Care and Research Center in Muscat, Oman, Dr. Usmani played a pivotal role in establishing the first theranostic facility in Oman in 2023, offering 177Lu-DOTATATE and 177Lu-PSMA therapies. His pioneering work in Kuwait includes establishing the 177Lu-PSMA therapy in 2014, a groundbreaking treatment targeting prostate-specific membrane antigen (PSMA) that revolutionized advanced prostate cancer management. He further advanced radionuclide therapy by introducing the highly precise 225Ac-PSMA therapy in 2017 and initiating the 177Lu-DOTATATE therapy for neuroendocrine tumors (NET) in 2019. A Fellow of the European Board of Nuclear Medicine (2007), the Asian Nuclear Medicine Board (2018), and the Royal College of Physicians of Edinburgh (2019), Dr. Usmani served as a teaching staff at the Kuwait Institute of Medical Specialization, Oman Medical Specialty Board and holds an Honorary Senior Lecturer position at Hull York Medical School, United Kingdom. He has been recognized with the Outstanding Doctor Award at the Kuwait Cancer Control Center (2016) and the Most Hardworking House Officer Award at the Department of Medicine, Civil Hospital Karachi, Pakistan (2002). Dr. Usmani has served on the editorial boards of numerous cancer research journals and is currently a review editor for Nuclear Medicine at Frontiers in Medicine. His main research interests lie in bone imaging with 18F-NaF PET/CT in non-oncological indications and 68Ga-PSMA imaging in prostate cancer.